ClinicalTrials.gg
RecruitingNCT07141355EMPAmicroSHOCKUpdated Aug 20, 2026

Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

An interventional study of microcirculation using the video microscopy tool. in Cardiogenic Shock, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.

Planned enrollment
23rd of 25
24 · median 164
Started
2025
with 5 others
No phase
13 of 62
6 open now
Primary completion
2027-08
later than 14 of 20 live
Registered
59th of 62
by date
Lead sponsor
5 of 62
University Hospital, Strasbourg, France

Among the 62 studies in Shock, Cardiogenic with a site in France, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 with no phase, reaches primary completion later than 14 of the 20 other live ones, and was the 59th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Shock, Cardiogenic with a site in France, or all of them as a file.
02

Study summary

Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.

Growing evidence suggests that cardiogenic shock isn't just a problem of systemic macrocirculation (blood pressure, cardiac output). It also involves significant abnormalities in the systemic microcirculation. In fact, these microcirculatory parameters have proven to be better predictors of patient outcomes than traditional macrocirculatory measures.

Given its known vasculo-protective effects on the endothelium, empagliflozin may have a beneficial impact on the microcirculation, potentially explaining its positive effects in cardiogenic shock.

This study will explore this hypothesis by analyzing the microcirculation in real-time using the CytoCam-IDF imaging videomicroscope and its MicroTools software. The goal is to gain a deeper understanding of how empagliflozin affects the microcirculation during cardiogenic shock.

Read the detailed description

This ancillary pilot study, conducted in an ICU, investigates the real-time microcirculatory effects of empagliflozin in patients with cardiogenic shock (CS). The study aims to determine if the drug improves microcirculation, which is a known predictor of patient outcomes in CS.

Upon a patient's inclusion in the main EMPASHOCK trial, consent for this ancillary study is obtained from the patient's family, with direct patient consent sought later if their condition improves.

The study involves two data collection points:

Baseline (H0): Before empagliflozin administration, a videomicroscope is used to capture sublingual microcirculation images. These images are analyzed using MicroTools software to measure key microcirculatory parameters. Standard macrocirculatory parameters (blood pressure, cardiac output) are also recorded.

48 Hours (H48): The same microcirculatory and macrocirculatory data are collected again to assess changes following treatment.

For patients in the non-empagliflozin group, assessment will be perform at inclusion (H0) and at H48.

The study's primary outcomes are the changes in these parameters over 48 hours, along with the patient's survival status at day 28.

03

Conditions studied

  • Cardiogenic Shock

Keywords

  • Cardiogenic Shock
  • Acute Heart failure
  • Heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient included in the main EMPASHOCK study
  • Patient has signed a consent form for the ancillary study
  • Patient is over 18 years old
  • Hospitalized in the Intensive Care Unit for cardiogenic shock*
  • Has been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock**
  • Patient has the ability to take tablets orally
  • Person is affiliated with or a beneficiary of a social security system

Exclusion criteria

Exclusion Criteria:

    • \< 20 ml/min/1.73m²

      • Chronic dialysis
      • Patient on SGLT2 inhibitors prior to ICU admission
      • Known allergy to SGLT2 inhibitors or any of their (in particular, patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome).
      • Patient on lithium
      • Patient with type 1 diabetes
      • Patient in shock due to another cause or moribund patient (IGS 2 > 90)
      • Cardiogenic shock cases excluded in the EMPASHOCK study: a. Heart transplant recipient or on a transplant list. b. Peripartum, adrenergic, valvular, restrictive, or post-embolic cardiomyopathy. c. Related to cardiotropic drug intoxication. d. Secondary to cardiac arrest where the patient remains comatose before inclusion.
      • Woman of childbearing age without effective
      • Person referred to in Articles 10, 31, 32, 33, and 34 of EU Regulation 536/2014, specifically:
  • Pregnant woman, woman in labor, or breastfeeding mother
  • Minor person (not emancipated)
  • Adult person subject to a legal protection measure (guardianship, curatorship, legal safeguard)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Patient in cardiogenic shock under empagliflozin

    Subgroup of patients from the EMPASHOCK trial, in which microcirculation parameters will be evaluated at inclusion (before being under empagliflozin treatment) and again after 48 hours.

    Diagnostic Test: microcirculation using the video microscopy tool.

  • Sham comparator
    Patient in cardiogenic shock without empagliflozin

    Subgroup of patients from the EMPASHOCK trial, without empagliflozin, in which microcirculation parameters will be evaluated at inclusion and again after 48 hours.

    Diagnostic Test: microcirculation using the video microscopy tool.

Interventions

  • Diagnostic testmicrocirculation using the video microscopy tool.

    The study intervention is the assessment of microcirculation using the video microscopy tool. This study's primary purpose is to perform this specific diagnostic procedure-measuring microcirculatory parameters with the CytoCam-IDF device-at two distinct time points: at inclusion (H0) and again 48 hours later (H48). The administration of empagliflozin (or not), which is pa and 48 hours after initiating empagliflozin treatment, microcirculatory data will be collected using a videomicroscope. A camera, roughly the size of a large pen, is placed under the patient's tongue for a few seconds to acquire images of the sublingual microcirculation. The entire image acquisition process takes less than 5 minutes and is unaffected by whether the patient is intubated. Images are then analyzed in real-time by the MicroTools software, which calculates key microcirculatory parameters. All anonymized images are stored on a dedicated, password-protected computer accessible only to the investigators.

06

What researchers measure

Primary outcomes

  1. The difference in the evolution of a parameter reflecting the microcirculation between the two groups at 48 hours post-randomization.

    To estimate the effect of the early introduction of empagliflozin, in addition to usual care versus usual care alone, at 48 hours post-randomization, on sublingual microcirculation.(functional capillary density (FCD)) with the CytoCam-IDF imaging videomicroscope and its MicroTools software

    Time frame: Comparison between Day 0 and 48 hours

Secondary outcomes

  1. Correlation between microcirculation parameters and macrocirculation parameters.

    Cardiac power index

    Time frame: Comparison between Day 0 and 48 hours

  2. The difference in the evolution of other microcirculation parameters between the two groups at 48 hours.

    Total vessel density (TVD)

    Time frame: Comparison between Day 0 and 48 hours

  3. The difference in the evolution of other microcirculation parameters between the two groups at 48 hours.

    Proportion of perfused vessels (PPV)

    Time frame: Comparison between Day 0 and 48 hours

  4. The difference in the evolution of other microcirculation parameters between the two groups at 48 hours.

    Functional capillary density (FCD),

    Time frame: Comparison between Day 0 and 48 hours

  5. The difference in the evolution of other microcirculation parameters between the two groups at 48 hours.

    Red blood cell mean velocity (RBCv)

    Time frame: Comparison between Day 0 and 48 hours

  6. The difference in the evolution of other microcirculation parameters between the two groups at 48 hours.

    Per-capillary microcirculatory flow index (MFI)

    Time frame: Comparison between Day 0 and 48 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 20 months is below that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 26, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07141355
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Dec 12, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion